Amended Statement of Beneficial Ownership (sc 13d/a)
13 8월 2021 - 7:08PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of
1934
(Amendment No. 9)*
USANA
Health Sciences, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
90328M107
(CUSIP Number)
Dr. Myron W. Wentz
c/o USANA Health Sciences, Inc.
3838
West Parkway Boulevard
Salt Lake City, Utah 84120
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 11, 2021
(Date of Event Which Requires Filing of
This Statement)
If the filing person has previously filed a statement
on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§
240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies
are to be sent.
|
*
|
The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 90328M107
1
|
NAMES OF REPORTING PERSONS
Gull Global Limited
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS):
OO
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E)
|
6
|
CITIZEN OR PLACE OF ORGANIZATION
The Bahamas
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH:
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
7,985,743
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
7,985,743
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,985,743
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
39.9%
|
14
|
TYPE OF REPORTING PERSON
OO
|
|
|
|
|
CUSIP No. 90328M107
1
|
NAMES OF REPORTING PERSONS
Myron W. Wentz
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
¨
(b) ¨
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS):
OO
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E)
|
6
|
CITIZEN OR PLACE OF ORGANIZATION
St. Kitts & Nevis
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH:
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
7,985,743
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
7,985,743
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,985,743
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
39.9%
|
14
|
TYPE OF REPORTING PERSON
IN
|
|
|
|
|
Explanatory Note:
This Amendment No. 9 (this “Amendment No.
9”) amends the statement on Schedule 13D filed with the Securities and Exchange Commission (the “Commission”) on May
23, 2008 by Myron W. Wentz (“Dr. Wentz”) and certain other reporting persons named therein, and amended by Amendment No. 1
thereto filed on May 22, 2018, Amendment No. 2 thereto filed on June 1, 2018, Amendment No. 3 thereto filed on August 7, 2018, Amendment
No. 4 thereto filed on October 2, 2018, and Amendment No. 5 thereto filed on February 11, 2020, Amendment No. 6 filed on May 7, 2020,
Amendment No. 7 filed on August 24, 2020, and Amendment No. 8 thereto filed on March 11, 2011, by Dr. Wentz and Gull Global Limited (“Gull
Global”) (as so amended, the “Schedule 13D”), relating to the common stock, par value $0.001 per share (“Shares”
or “Common Stock”), of USANA Health Sciences, Inc., a Utah corporation. This Amendment No. 9 reflects changes to items 5 and
7 of the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 9 shall have the meanings set forth in the Schedule
13D as amended prior to this Amendment No. 9.
|
Item 5.
|
Interest in Securities of the Issuer.
|
Item 5 of the Schedule 13D is hereby amended and
restated in its entirety as follows:
(a) Gull
Global is the direct beneficial owner of 7,985,743 Shares, constituting approximately 39.9% of the outstanding Shares, based on
20,012,274 Shares outstanding as of August 6, 2021 as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Commission
on August 11, 2021 (and which constituted approximately 39.46% of the outstanding Shares, based on 20,236,693 Shares outstanding as of
May 7, 2021 as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Commission on May 11, 2021). Dr. Wentz is deemed
to be the beneficial owner of the 7,985,743 Shares, constituting approximately 39.9% of the outstanding Shares, held by Gull Global (and
which constituted approximately 39.46% of the outstanding Shares, based on 20,236,693 Shares outstanding as of May 7, 2021 as reported
by the Issuer in its Quarterly Report on Form 10-Q filed with the Commission on May 11, 2021). The increases in the percentage of Shares
beneficially owned by the Reporting Persons that are reported on this Amendment No. 9 are due to decreases in the total number of Shares
outstanding as a result of share repurchases by the Issuer.
(b) The
Reporting Persons share the power to vote or direct the vote of the Shares beneficially owned by them, and the power to dispose of or
direct the disposition of such Shares.
(c) Neither
the Reporting Persons nor, to the best of the Reporting Persons’ knowledge, any person named in Item 2 of the Schedule 13D, has
effected any other transactions in the Common Stock during the 60-day period prior to the date of this Amendment No. 9 or May 11, 2021.
|
Item 7.
|
Material to Be Filed as Exhibits.
|
Item 7 of
the Schedule 13D is hereby amended and supplemented by adding reference to the following exhibit filed with this Amendment No. 9:
|
Exhibit 1
|
Joint Filing Agreement
|
SIGNATURES
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: August 12, 2021
|
Gull Global Limited
|
|
|
|
|
|
|
By:
|
/s/ Valarie A. Hing
|
|
|
Name:
|
Valarie A. Hing
|
|
|
Title:
|
Attorney in Fact
|
|
|
|
|
|
|
|
|
|
|
MYRON W. WENTZ
|
|
|
|
|
|
|
By:
|
/s/ Valarie A. Hing
|
|
|
Name:
|
Valarie A.
Hing
|
|
|
Title:
|
Attorney in Fact
|
|
Exhibit 1
JOINT FILING AGREEMENT
Each of the undersigned hereby agrees
that this Amendment No. 9 to the statement on Schedule 13D is being filed with the Securities and Exchange Commission on behalf
of each of the undersigned pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Dated: August 12, 2021
|
Gull Global Limited
|
|
|
|
|
|
|
By:
|
/s/ Valarie A. Hing
|
|
|
Name:
|
Valarie A. Hing
|
|
|
Title:
|
Attorney in Fact
|
|
|
|
|
|
|
|
|
|
|
MYRON W. WENTZ
|
|
|
|
|
|
|
By:
|
/s/ Valarie A. Hing
|
|
|
Name:
|
Valarie A.
Hing
|
|
|
Title:
|
Attorney in Fact
|
|
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024